Fraud Risks Involving Oral GLP-1 Therapies and Wegovy

As the market for GLP-1 weight loss medications continues to expand, the introduction of oral formulations has created new opportunities for fraud, waste, and abuse (FWA). While oral GLP-1 therapies may improve patient access and convenience, they also introduce additional pharmacy benefit vulnerabilities, particularly when used alongside injectable products such as Wegovy. Health plans, PBMs, […] The post Fraud Risks Involving Oral GLP-1 Therapies and Wegovy appeared first on Codoxo .